Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ Transplantation

Posttransplant infusion of viable donor bone marrow cells (DBMC) has been shown in our previous studies to promote acceptance of incompatible kidney allografts in rhesus monkeys after treatment with polyclonal antithymocyte globulin to deplete peripheral T-lymphocytes. In this nonhuman primate model...

Full description

Bibliographic Details
Main Authors: J. P. Smith, J. Kasten-Jolly, L. Rebellato, Carl E. Haisch, Judith M. Thomas
Format: Article
Language:English
Published: SAGE Publishing 1997-07-01
Series:Cell Transplantation
Online Access:https://doi.org/10.1177/096368979700600403
id doaj-75aeee3c9d504609b11a5d11c2a949c6
record_format Article
spelling doaj-75aeee3c9d504609b11a5d11c2a949c62020-11-25T03:39:28ZengSAGE PublishingCell Transplantation0963-68971555-38921997-07-01610.1177/096368979700600403Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ TransplantationJ. P. Smith0J. Kasten-Jolly1L. Rebellato2Carl E. Haisch3Judith M. Thomas4Departments of Anatomy and Surgery, East Carolina University, Greenville, NC, USAThe State University of New York at Buffalo, Buffalo, NY, USATransplant Immunobiology Division, Transplant Center, The University of Alabama at Birmingham, Birmingham, AL 35294, USATransplant Immunobiology Division, Transplant Center, The University of Alabama at Birmingham, Birmingham, AL 35294, USATransplant Immunobiology Division, Transplant Center, The University of Alabama at Birmingham, Birmingham, AL 35294, USAPosttransplant infusion of viable donor bone marrow cells (DBMC) has been shown in our previous studies to promote acceptance of incompatible kidney allografts in rhesus monkeys after treatment with polyclonal antithymocyte globulin to deplete peripheral T-lymphocytes. In this nonhuman primate model, the infusion of the DBMC is requisite for the induction of functional graft tolerance and specific MLR and CTLp unresponsiveness, although the relevant role and fate of bone marrow-derived chimeric cells is uncertain. Standard immunological and molecular techniques applied to this monkey model are unable to differentiate between chimeric cells derived from the infused DBMC and those derived from allograft-borne passenger leukocyte emigrants. To distinguish chimerism due to infused DBMC, we transduced DBMC with a functional neomycin resistance gene (Neo r ) using the retroviral vector pHSG-Neo. Neo r -Mransduced BMC were infused into recipients approximately 2 wk after kidney transplantation and treatment with rabbit antithymocyte globulin. No maintenance immunosuppressive drugs were given. Genomic DNA isolated from peripheral blood leukocytes was used to monitor the presence of Neo r -positive cells. Tissue samples obtained at necropsy also were assessed for Neo r -positive chimeric cells. The presence of DBMC-derived chimerism was assessed by polymerase chain reaction using Neo r sequence-specific primers (PCR-SSP). Chimerism was detectable in recipient tissues at various times for up to 6 mo after DBMC infusion. These studies using gene transduction methodology indicate that a stable genetic marker can provide capability to examine DBMC-derived chimerism for prolonged periods in a nonhuman primate model. This approach should facilitate future studies in preclinical models to study the role and type of chimeric cell lineages in relation to functional allograft tolerance.https://doi.org/10.1177/096368979700600403
collection DOAJ
language English
format Article
sources DOAJ
author J. P. Smith
J. Kasten-Jolly
L. Rebellato
Carl E. Haisch
Judith M. Thomas
spellingShingle J. P. Smith
J. Kasten-Jolly
L. Rebellato
Carl E. Haisch
Judith M. Thomas
Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ Transplantation
Cell Transplantation
author_facet J. P. Smith
J. Kasten-Jolly
L. Rebellato
Carl E. Haisch
Judith M. Thomas
author_sort J. P. Smith
title Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ Transplantation
title_short Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ Transplantation
title_full Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ Transplantation
title_fullStr Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ Transplantation
title_full_unstemmed Use of Allogeneic Bone Marrow Labeled with Neomycin Resistance Gene to Examine Bone Marrow-Derived Chimerism in Experimental Organ Transplantation
title_sort use of allogeneic bone marrow labeled with neomycin resistance gene to examine bone marrow-derived chimerism in experimental organ transplantation
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 1997-07-01
description Posttransplant infusion of viable donor bone marrow cells (DBMC) has been shown in our previous studies to promote acceptance of incompatible kidney allografts in rhesus monkeys after treatment with polyclonal antithymocyte globulin to deplete peripheral T-lymphocytes. In this nonhuman primate model, the infusion of the DBMC is requisite for the induction of functional graft tolerance and specific MLR and CTLp unresponsiveness, although the relevant role and fate of bone marrow-derived chimeric cells is uncertain. Standard immunological and molecular techniques applied to this monkey model are unable to differentiate between chimeric cells derived from the infused DBMC and those derived from allograft-borne passenger leukocyte emigrants. To distinguish chimerism due to infused DBMC, we transduced DBMC with a functional neomycin resistance gene (Neo r ) using the retroviral vector pHSG-Neo. Neo r -Mransduced BMC were infused into recipients approximately 2 wk after kidney transplantation and treatment with rabbit antithymocyte globulin. No maintenance immunosuppressive drugs were given. Genomic DNA isolated from peripheral blood leukocytes was used to monitor the presence of Neo r -positive cells. Tissue samples obtained at necropsy also were assessed for Neo r -positive chimeric cells. The presence of DBMC-derived chimerism was assessed by polymerase chain reaction using Neo r sequence-specific primers (PCR-SSP). Chimerism was detectable in recipient tissues at various times for up to 6 mo after DBMC infusion. These studies using gene transduction methodology indicate that a stable genetic marker can provide capability to examine DBMC-derived chimerism for prolonged periods in a nonhuman primate model. This approach should facilitate future studies in preclinical models to study the role and type of chimeric cell lineages in relation to functional allograft tolerance.
url https://doi.org/10.1177/096368979700600403
work_keys_str_mv AT jpsmith useofallogeneicbonemarrowlabeledwithneomycinresistancegenetoexaminebonemarrowderivedchimerisminexperimentalorgantransplantation
AT jkastenjolly useofallogeneicbonemarrowlabeledwithneomycinresistancegenetoexaminebonemarrowderivedchimerisminexperimentalorgantransplantation
AT lrebellato useofallogeneicbonemarrowlabeledwithneomycinresistancegenetoexaminebonemarrowderivedchimerisminexperimentalorgantransplantation
AT carlehaisch useofallogeneicbonemarrowlabeledwithneomycinresistancegenetoexaminebonemarrowderivedchimerisminexperimentalorgantransplantation
AT judithmthomas useofallogeneicbonemarrowlabeledwithneomycinresistancegenetoexaminebonemarrowderivedchimerisminexperimentalorgantransplantation
_version_ 1724538600737996800